RxSight reports preliminary Q2 revenue, revises 2026 guidance
Seeking Alpha ·
RxSight ( NASDAQ: RXST ) announced on Monday that preliminary Q2 revenue is expected at $32M-$34M, including $5M-$7M from its strategic collaboration with Alcon. Product sales are expected to total about $27M, including 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, with one
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
508 participants
Related News
- Why Microsoft cut 3,200 Xbox jobs
- Lockheed Martin wins $142.9M C-5 Galaxy software support contract
- Hyper Bit Technologies launches C$1.5M private placement
- Seagate, Semtech, and Teradyne Stocks Trade Up, What You Need To Know
- Apple's $2,500 foldable iPhone could sell out instantly
- Why Abacus Global Management Stock Inched Higher Today